ALLN-177

DRUG4 trials

Sponsors

Allena Pharmaceuticals

Conditions

Dietary HyperoxaluriaEnteric HyperoxaluriaHyperoxalemiaHyperoxaluriaKidney StonesNephrolithiasisPrimary HyperoxaluriaSecondary Hyperoxaluria

Phase 2

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

CompletedNCT02289755

Allena PharmaceuticalsHyperoxaluria, Nephrolithiasis

Start: 2014-09-30End: 2015-02-28Updated: 2019-06-05

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

CompletedNCT02547805

Allena PharmaceuticalsDietary Hyperoxaluria, Hyperoxaluria, Kidney Stones +2

Start: 2015-09-30End: 2017-01-31Updated: 2017-01-19

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

CompletedNCT03391804

Allena PharmaceuticalsEnteric Hyperoxaluria, Hyperoxalemia, Primary Hyperoxaluria

Start: 2018-07-17End: 2019-12-13Updated: 2020-12-30

Phase 3

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

CompletedNCT03456830

Allena PharmaceuticalsEnteric Hyperoxaluria

Start: 2018-05-21End: 2019-10-28Updated: 2020-02-27

Related Papers

Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria

NEJM Evidence2022-05-0616 citations

ALLN-177, oral enzyme therapy for hyperoxaluria.

2019-02-1928 citations